FindTrial
Sign In

Audit of Anti Glaucoma Drug Utilization and their effects on ocular surface

Clinical Audit of Anti-Glaucoma Drug Utilization Pattern and their impact on ocular surface - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/094422
Enrollment
104
Registered
2025-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma Health Condition 2: H402- Primary angle-closure glaucoma

Interventions

Intervention1: Nil: Nil

Sponsors

Guru Nanak Eye Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with primary glaucoma of age 18 years and Above on more than 1 anti- glaucoma drops of more Than 3 month duration

Exclusion criteria

Exclusion criteria: Pre existing diagnosis of ocular surface disease Eg dry eyes Prior intra ocular surgery within 12 months of enrollment Allergic conjunctival disorders Patients having systemic disorders eg Diabetes Mellitus

Design outcomes

Primary

MeasureTime frame
Clinical audit of drug utilization practices in glaucoma referralsTimepoint: 52 weeks—

Secondary

MeasureTime frame
Proportion of patients using anti glaucoma drugs having meibomian gland dysfunction Meiboscale by Phoenix software Proportion of patients having polypharmacy associated ocular side effectsTimepoint: 52 weeks—

Countries

India

Contacts

Public ContactDIKSHA KUMAR

Guru Nanak Eye Centre

kumardiksha2016@gmail.com8585951122

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026